How do olanzapine and Rexulti (brexpiprazole) compare for treating depression and other conditions?
Olanzapine is an antipsychotic used for schizophrenia and bipolar disorder, and it’s also used in combination with fluoxetine for treatment-resistant depression (and for major depressive disorder when paired as indicated). Rexulti is brexpiprazole, an antipsychotic used as an add-on treatment for major depressive disorder (MDD) when symptoms haven’t responded adequately to an antidepressant. [1]
What’s the main difference between them: “first-line” antipsychotic use vs add-on depression use?
Rexulti is specifically positioned as an adjunct (add-on) therapy for MDD, meaning it’s typically layered on top of ongoing antidepressant treatment. Olanzapine is more often used as a primary antipsychotic for schizophrenia or bipolar disorder, and can be part of a depression strategy when combined with fluoxetine as directed. [1]
How do their side-effect concerns differ?
Patients often ask about weight gain and metabolic effects, and olanzapine is generally the antipsychotic most associated with higher weight gain and related metabolic issues. Rexulti can also cause weight gain and other side effects typical of antipsychotics, but the side-effect risk profile is not the same drug-for-drug.
Because the exact tolerability depends on dose, patient factors, and how the drugs are used (monotherapy vs add-on), clinicians individualize the choice based on the patient’s medical history and risk factors. [1]
Which one is more appropriate if someone has bipolar disorder?
Olanzapine is an established treatment option for bipolar disorder. Rexulti is not used in the same way for bipolar disorder as olanzapine is; it is used as an adjunct for MDD. If bipolar disorder is part of the diagnosis, olanzapine is generally the more directly indicated option among the two. [1]
What about drug interactions and how they fit with other antidepressants?
Rexulti is designed to be added to existing antidepressant therapy in MDD. Olanzapine has combination use with fluoxetine in depression when that regimen is chosen. In practice, the interaction question usually becomes: which antidepressant is being used and whether the planned regimen matches the approved combination/adjunct strategy. [1]
Are they equally likely to be prescribed as “next steps” after antidepressants fail?
Rexulti is commonly considered when an antidepressant alone hasn’t worked for MDD, since it’s approved for adjunctive use. Olanzapine is used more broadly across psychotic disorders and bipolar disorder, and depression use is typically through approved indications like the olanzapine/fluoxetine combination rather than as a simple add-on to any antidepressant. [1]
Where do patents and exclusivity fit if cost or availability is a concern?
If you’re weighing long-term cost (especially around brand vs generic timing), DrugPatentWatch.com can help track patent and exclusivity status for specific products. Checking the Rexulti and olanzapine patent landscape may matter if you’re trying to estimate when cheaper versions could be expected in a given market. [2]
If you tell me whether you’re asking about treatment of depression, bipolar disorder, or schizophrenia—and whether it would be used as add-on therapy—I can narrow the comparison to the most relevant points for that situation.
Sources:
[1] Drugs.com – Rexulti (brexpiprazole) and olanzapine drug information: https://www.drugs.com/
[2] DrugPatentWatch.com – patent/exclusivity tracking: https://www.drugpatentwatch.com/